Autor: |
Minghui Li, Weihua Cao, Tingting Jiang, Wen Deng, Shiyu Wang, Shuling Wu, Lu Zhang, Yao Lu, Min Chang, Ruyu Liu, Xiaoyan Ding, Ge Shen, Yuanjiao Gao, Hongxiao Hao, Xiaoxue Chen, Leiping Hu, Mengjiao Xu, Yuyong Jiang, Wei Yi, Yao Xie, Rui Song |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Biosafety and Health, Vol 6, Iss 3, Pp 165-170 (2024) |
Druh dokumentu: |
article |
ISSN: |
2590-0536 |
DOI: |
10.1016/j.bsheal.2024.04.004 |
Popis: |
To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (P = 0.003) and immunosuppressant (P = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (P = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (P = 0.018). Logistic regression analysis showed that UDCA use (P = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (P = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (P = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|